We are monitoring the impact of COVID-19 on Europe Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 835
Share on
Share on

Europe Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 835
Pages: 145

Europe Lung Cancer Therapeutics Market Size (2021 to 2026)

The Europe Lung Cancer Therapeutics Market size is estimated to worth USD 2.43 billion by 2026 from USD 1.78 billion in 2021, registering a CAGR of 6.47% during the forecast period. Europe is the second-largest region for the lung cancer therapeutics market.

Lung cancer diagnoses have grown due to increasing cancer awareness and introducing new medical diagnostic equipment and advanced therapies, driving the lung cancer therapeutics market forward in Europe. Lung cancer is a kind of cancer that develops in the tissues of the lungs. It's also known as pulmonary carcinoma, and it's characterized by uncontrolled lung tissue development. The expanding elderly population, changing lifestyles, and rising tobacco smoking, including passive smoking, are all likely drivers for the European lung cancer therapeutics market. Furthermore, factors such as focused and ground-breaking medication delivery to the lungs and the growing acceptance of customized therapies are viewed as key contributors driving the overall market of Europe Lung cancer therapeutics.

Lung cancer is becoming more common due to increased financing for the development of new medicines, increased pollution due to fast industrialization, and increased smokers. As a result, all of these factors have contributed to the Europe Lung cancer therapeutics market's expansion. The entire market has grown as the expense of cancer therapy has increased, as has the price of drugs. Furthermore, significant investments in development have aided the development of cancer treatments. Additionally, favorable government regulations for cancer treatments, as well as an increase in cancer prevalence, have fueled Europe's Lung cancer therapeutics market development.

The restricted treatment choices, widespread availability of generic critical medicines, and the large unmet need for diagnostics are expected to be the key factors limiting the Europe Lung cancer therapeutics market's growth. In addition, the market's growth has been stifled by the adverse effects of therapeutic interventions, side effects in the future, and the high cost of the therapies.

Adverse effects from radiation and chemotherapies are also a primary challenge. The expiration of patents on current drugs may have a negative influence on the industry. As a result, the industry's key companies must focus on safer medicines and innovative remedies.

This research report on the Europe Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:

By Treatment Type:

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic 
  • Rest of Europe

Regionally, U.K is the leading market due to a high population base suffering from lung cancer, while Germany is anticipated to witness high growth in the forecast period. Europe is anticipated to be the second biggest market for lung cancer treatments due to significant government funding in the research and development of novel drugs, rising regulatory approvals, and technical advances in the area of cancer. In addition, increased adoption of advanced lung cancer treatments and rising lung cancer prevalence and diagnosis are anticipated to fuel growth in the area. One of the most important driving reasons for the growth of the lung cancer therapeutics market is the rising acceptance and demand for targeted treatments, which is considered to be the basis of precision medicine due to increased R&D activities. Other factors contributing to Europe's growing cancer rates include poor lifestyles and inappropriate diets, obesity, and a lack of physical activity. As a result, throughout the forecast period, the rising incidence and prevalence of cancer would likely fuel the expansion of the cancer treatments market in Europe.

KEY MARKET PLAYERS:

A few of the notable companies operating in the Europe Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 U.K                                

                6.3 Spain                                             

                6.4 Germany                                     

                6.5 Italy                                               

                6.6 France                                          

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 BoehringerIngelheim GmbH                               

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Hoffman-La Roche                                  

                8.3 Pfizer Inc.                                    

                8.4 GlaxoSmitKline                                         

                8.5 Eli Lilly and Company                                             

                8.6 AstrazenecaPlc                                         

                8.7 Sanofi-Aventis                                          

                8.8 Agennix AG                                

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures        

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Europe Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  3. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Radiotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  6. U.K Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  7. Spain Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  8. Germany Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  9. Italy Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  10. France Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  11. Europe Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  12. Europe Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Taxol Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Navelbine Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Camptosar Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe Alimta Market, By Region, From 2021 to 2026 (USD Billion)
  17. U.K Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  18. Spain Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  19. Germany Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  20. Italy Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  21. France Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  22. Europe Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  23. Europe External Beam Market, By Region, From 2021 to 2026 (USD Billion)
  24. Europe Internal Beam Market, By Region, From 2021 to 2026 (USD Billion)
  25. Europe Systemic Market, By Region, From 2021 to 2026 (USD Billion)
  26. U.K Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  27. Spain Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  28. Germany Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  29. Italy Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  30. France Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  31. Europe Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  32. Europe Abraxane Market, By Region, From 2021 to 2026 (USD Billion)
  33. Europe Avastin Market, By Region, From 2021 to 2026 (USD Billion)
  34. Europe Crizotinib Market, By Region, From 2021 to 2026 (USD Billion)
  35. Europe Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  36. Europe Gefitinib Market, By Region, From 2021 to 2026 (USD Billion)
  37. U.K Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  38. Spain Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  39. Germany Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  40. Italy Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  41. France Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample